Chapman and Hall/CRC
454 pages | 60 B/W Illus.
Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis provides statisticians with an understanding of the critical challenges currently encountered in oncology trials. Well-known statisticians from academic institutions, regulatory and government agencies (such as the U.S. FDA and National Cancer Institute), and the pharmaceutical industry share their extensive experiences in cancer clinical trials and present examples taken from actual trials.
The book covers topics that are often perplexing and sometimes controversial in cancer clinical trials. Most of the issues addressed are also important for clinical trials in other settings. After discussing general topics, the book focuses on aspects of early and late phase clinical trials. It also explores personalized medicine, including biomarker-based clinical trials, adaptive clinical trial designs, and dynamic treatment regimes.
"The chapters on endpoints and safety are a must read for anyone working in this field. And for statisticians involved in the design of cancer trials, the diverse options of design and sample size calculations are well covered."
~International Society for Clinical Biostatistics
"This book provides a comprehensive summary of common controversial issues frequently encountered in oncology trials. Individual issues are addressed by well-known statisticians from academic institutions, regulatory, and government agencies and pharmaceutical industry. In summary, this is an excellent book covering commonly encountered controversial issues for cancer clinical trials. It can be an excellent resource for statisticians working in oncology drug development."
~Journal of Biopharmaceutical Graphics, Steven Sun
Endpoints for Cancer Clinical Trials
Stephen L. George, Xiaofei Wang, and Herbert Pang
Use of Historical Data
Simon Wandel, Heinz Schmidli, and Beat Neuenschwander
Dong Xi, Ekkehard Glimm, and Frank Bretz
Analysis of Safety Data
Steven Snapinn and Qi Jiang
Early Phase Clinical Trials
Development and Validation of Predictive Signatures
Michael C. Sachs and Lisa M. McShane
Phase I Trials and Dose-Finding
Mark R. Conaway and Nolan A. Wages
Design and Analysis of Phase II Cancer Clinical Trials
Late Phase Clinical Trials
Sample Size for Survival Trials in Cancer
Rajeshwari Sridhara and Thomas Gwise
Quality of Life
Biomarker-Based Clinical Trials
Edward L. Korn and Boris Freidlin
Adaptive Clinical Trial Designs in Oncology
J. Jack Lee and Lorenzo Trippa
Dynamic Treatment Regimes
Marie Davidian, Anastasios (Butch) Tsiatis, and Eric Laber